Marker Therapeutics provided a business and clinical update. Marker reported cash and cash equivalents totaling $61.7M as of December 31, 2018. Expects that current cash resources will be sufficient to meet operating requirements into Q4 of 2020. CEO Peter L. Hoang commented, “We plan to advance a Phase 2 Company-sponsored clinical trial in post-transplant acute myeloid leukemia – a disease area and patient population for which there are limited treatment options. We expect to finalize our clinical trial protocol in AML by the end of Q2 and to submit our IND in Q3, with the first patient enrolled by the end of the year. While our T cell therapies remain our primary clinical focus, we are also advancing our T cell vaccine candidates, TPIV200 and TPIV100/110, for the treatment of ovarian and breast cancers. Overall, there are two Phase 2 company-sponsored studies ongoing for TPIV200 in triple-negative breast cancer and ovarian cancer, and we anticipate reporting interim data from the ovarian cancer Phase 2 study in Q4.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.